Mengru Tian
Overview
Explore the profile of Mengru Tian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
10
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tian M, Wang S, Meng Z, Zhang X, Han J, Lu Y
Intractable Rare Dis Res
. 2025 Mar;
14(1):14-28.
PMID: 40046028
This study utilizes CiteSpace (version 6.2.R3) to visually analyze literature related to rare diseases, summarizing the current research status and hotspots in the field. The goal was to provide broader...
2.
Xu W, Liang X, Liu S, Yi X, Tian M, Yue T, et al.
Clin Med (Lond)
. 2024 Oct;
24(6):100252.
PMID: 39362336
Background: Minimal residual disease (MRD) testing is a promising approach to tailor the treatment of multiple myeloma (MM). However, several major concerns remain to be addressed before moving it into...
3.
Zhang Y, Liang X, Xu W, Yi X, Hu R, Ma X, et al.
J Hematol Oncol
. 2024 Jun;
17(1):48.
PMID: 38915117
It remains a substantial challenge to balance treatment efficacy and toxicity in geriatric patients with multiple myeloma (MM), primarily due to the dynamic nature of frailty. Here, we conducted a...
4.
Tian M, Liang X, Xu W, Yi X, Yue T, Zhang Y, et al.
Ann Hematol
. 2023 Jul;
102(10):2943-2945.
PMID: 37434095
No abstract available.
5.
Yang P, Xu W, Liang X, Yu S, Yi X, Liu M, et al.
Am J Hematol
. 2022 Dec;
98(3):E61-E64.
PMID: 36540935
No abstract available.
6.
Yang P, Chen H, Liang X, Xu W, Yu S, Huang W, et al.
Am J Hematol
. 2022 Oct;
98(2):251-263.
PMID: 36309982
1q gain (+1q) is the most common high-risk cytogenetic abnormality (HRCA) in patients with multiple myeloma (MM). However, its prognostic value remains unclear in the era of novel agents. Here,...